Hotbed/Location

Found 625,852 articles

• Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development

  7/27/2021

  Umoja Biopharma announced the appointments of three new hires in the company's research and business development functions, including Bruce Kerwin, Ph.D. as Senior Vice President of Process and Product Development, Ryan Larson, Ph.D. as Vice President and Head of Translational Science, and Mike Fitzpatrick as Vice President of Business Development and Operations.

• Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity

  7/27/2021

  Regeneron Pharmaceuticals, Inc. and AstraZeneca announced that the companies have entered into a collaboration to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

• LifeSignals receives FDA 510 (k) Approval for LifeSignals LX1550 Multiparameter Remote Monitoring Platform

  7/27/2021

  LifeSignals Inc., announced it has received FDA Class II 510 approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.

• Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

  7/27/2021

  Oragenics, Inc. announced it has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

• Bio-Techne Announces Commercial Release of RNAscope™ HiPlex V2 Assay for Single Cell Validation and Spatial Transcriptomic Profiling of Complex Tissues on FFPE, Fixed and Fresh Frozen Samples.

  7/27/2021

  Bio-Techne Corporation announced the expansion of the Advanced Cell Diagnostics, a Bio-Techne brand, RNAscope in situ hybridization technology portfolio with the release of new RNAscope HiPlex V2 assay for formalin-fixed paraffin-embedded and fixed and fresh frozen samples for up to 12 targets.

• Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021

  7/27/2021

  Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.

• Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma

  7/27/2021

  Day One Biopharmaceuticals announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead product candidate, DAY101, for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children.

• Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021

  7/27/2021

  Verastem Oncology announced that an abstract detailing updated results from the ongoing Phase 1/2 FRAME study investigating VS-6766, the Company’s RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low grade serous ovarian cancer has been selected for a mini oral presentation at the upcoming European Society of Medical Oncology Congress 2021, taking place virtually September 16-21, 2021.

• Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021

  7/27/2021

  Matinas BioPharma Holdings, Inc. announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021.

• Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement

  7/27/2021

  Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced it entered into an exclusivity agreement with ABX Advanced Biochemical Compounds GmbH for the supply of a key component required to manufacture the drug substance in Rhenium-186 NanoLiposome, the Company’s lead radiotherapeutic.

• IMIDomicsTM Closes $16.5 Million Series A Financing to Advance its Precision Discovery Platform for Immune-Mediated Inflammatory Diseases

  7/27/2021

  IMIDomics Inc., a drug discovery company focused on patients with immune-mediated inflammatory diseases, has announced the completion of a $16.5 million Series A financing round.

• Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs

  7/27/2021

  Tonix Pharmaceuticals Holding Corp. announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development facility in Frederick, MD to support Tonix’s expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.

• Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

  7/27/2021

  Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021.

• Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

  7/27/2021

  Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET.

• XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

  7/27/2021

  XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, announced the completion of the Phase 1 dose-escalation component of its Phase 1/2 clinical trial of XC001, its lead investigational gene therapy candidate for patients with refractory angina who have no further treatment options.

• BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel

  7/27/2021

  BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that is has received Good Manufacturing Practice approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.

• Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company

  7/27/2021

  The company is making great progress with delivering on the strategic priorities we defined on Day 1 of Idorsia.

• Pixium Vision announces its financial results for H1 2021 and provides a business update

  7/27/2021

  Paris, 27 July 2021 – 7.00 a.m. CET - Pixium Vision, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for the first half of 2021.

• Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

  7/27/2021

  Organon, a global women’s health company and ObsEva, a biopharmaceutical company dedicated to improving women’s reproductive health, announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant.

• Hyloris to Report 2021 Half-Year Results on 4 August 2021

  7/27/2021

  Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST to present its half-year 2021 financial results and to provide a business update.